Method for analyzing drug molecules in mammalian tissue
Transparent assisted tissue click chemistry (CATCH) method solves the observation problem of drug-target interaction in vivo at cell resolution through tissue transparency and CuAAC click reaction, combining confocal microscopy, and achieves high-resolution drug targets. Imaging and target cell type identification provide higher signal-to-noise ratio and spatial resolution.
Patent Information
- Application Number
- CN202380034227.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2023-03-15
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art is difficult to observe drug-target interactions at high resolution at the in vivo tissue level, especially at cell resolution. Traditional methods lack sufficient resolution and signal-to-noise ratio to achieve high resolution of drug-target interactions. Rate spatial imaging.
Transparent assisted tissue click chemistry (CATCH) method is used to transparentize tissue samples through degreasing agents, and CuAAC click reaction is carried out to label drug molecules. Combined with confocal microscopy and other analytical methods, in situ fluorescence imaging and targets of drug molecules are achieved. Identification.
Achieve specific and robust in situ fluorescence imaging of drug targets at subcellular resolution, able to identify target cell types and reveal anatomical distribution and dose-dependent target transfer of drugs in vivo, providing higher signal-to-noise ratios and Spatial resolution.
Smart Images

Figure CN119053710A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 321,294 (filed on March 18, 2022; currently pending). The entire disclosure of this priority application is incorporated herein by reference in its entirety for all purposes.
[0003] Government support statement
[0004] This invention was made with government support under Grant Nos. DK128800, DK114165, and DK124731 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art
[0005] Target identification and validation of small molecules has always been a long-standing challenge in chemical biology and drug discovery. Although significant progress has been made in detecting drug-target interactions at the molecular scale, these methods are generally not suitable for such relationships at the in vivo tissue level. Traditional pharmacokinetics and pharmacodynamics usually quantify drug concentrations or drug-target interactions in homogenized organs, eliminating the spatial resolution that is crucial to understanding target engagement in vivo. Imaging-based methods (such as positron emission tomography (PET)) are widely used to perform spectral analysis (profile) of small molecule distribution in vivo, but lack sufficient resolution to distinguish drug binding states at the cellular level to accurately identify drug-target interactions. The ideal method should allow in situ visualization of target-bound drugs at single-cell resolution, while being compatible with multiple molecular characterizations of its drug-target interactions. These goals are particularly important for drugs targeting the central nervous system, which has significant heterogeneity in cell composition and spatial organization.
[0006] Fluorescence optical microscopy has revolutionized high-resolution in situ imaging of endogenous biomolecules such as proteins and nucleic acids. However, exogenous small molecules are more difficult to image because the addition of fluorescent tags changes the size and chemical properties of the parent compound, potentially distorting drug distribution and on- and off-target engagement. Biorthogonal reactions, including the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click reaction, can partially address these issues by enabling the incorporation of larger tags after the drug reaches its target using a small and inert alkyne / azide pathway. Although this click chemistry (CC) strategy combined with chemical proteomics approaches such as activity-based protein profiling (CC-ABPP) has been shown to be effective for identifying drug targets in a variety of biological settings, including animal models, such approaches have not yet been able to achieve high-resolution spatial imaging of drug-target interactions in vivo due to the poor signal-to-noise ratio (SNR) in intact tissues.
[0007] There is a need in the art for more efficient tools to visualize drug-target interactions, especially at cellular resolution in intact tissues. The present invention is directed to addressing these and other unmet needs. Summary of the invention
[0008] In one aspect, the invention provides a method for analyzing drug molecules or their metabolites in mammalian tissues. These methods require (a) obtaining tissue samples from mammalian subjects to which drug molecules have been applied, (b) making tissue samples transparent (clearing) with a degreasing agent, (c) carrying out CuAAC reaction with labeled drug molecules with transparent tissue samples, and (d) checking drug molecules in tissue samples with analytical means. In some methods, drug molecules to be analyzed are small molecules. In some methods, drug molecules to be analyzed are covalent drugs. In some different embodiments, the degreasing agent used can be a tissue transparent agent, a hydrophobic tissue transparent agent, a hydrophilic tissue transparent agent or a combination thereof based on a hydrogel.
[0009] In some preferred embodiments, a CuAAC click reaction is performed on a cleared tissue sample to label a drug molecule with a fluorophore. In some embodiments, the CuAAC reaction employed in the methods of the present invention is optimized. In some of these embodiments, the optimized CuAAC reaction uses about 100 μM to about 150 μM Cu 2+concentration. In some embodiments, the CuAAC reaction is optimized by including a pre-incubation of the cleared tissue prior to starting the click reaction. In some embodiments, the CuAAC reaction is optimized with a click reaction ligand that improves the signal-to-noise ratio. In various embodiments, the click reaction ligand employed can be, for example, BTTP, THPTA, or BTTAA.
[0010] Generally speaking, the drug molecule or its metabolite to be analyzed in the method of the present invention comprises an alkynyl or alkyne analog suitable for a click reaction. In some preferred embodiments, the analytical means for examining the drug molecule in a tissue sample that has been cleared and labeled by a click reaction is an imaging means. For example, some preferred methods of the present invention may employ confocal microscopy to examine labeled drug molecules in a tissue sample.
[0011] In addition to examining drug molecules in tissue samples that have been cleared and labeled with a click reaction, some methods of the invention may further include staining tissue samples with reagents directed to cell types that are known or suspected to express the target of the drug molecule. In some of these embodiments, the staining agent employed is an antibody or nucleic acid probe that is specific to the cell type.
[0012] In a related aspect, the present invention provides a method for identifying the target of a drug molecule in a mammalian tissue. These methods include: (a) obtaining a tissue sample from a mammalian subject to which the drug molecule has been applied, (b) making the tissue sample transparent with a degreasing agent, (c) performing a CuAAC reaction with a transparent tissue sample to label the drug molecule, and (d) using an analytical means to check the drug molecule in the tissue sample to identify the target of the drug molecule in the tissue. Some of these methods are intended to identify the target of a small molecule drug molecule. Some of these methods are intended to identify the target of a covalent drug molecule. In a plurality of embodiments, the tissue clearing agent used is a tissue clearing agent, a hydrophobic tissue clearing agent, or a hydrophilic tissue clearing agent based on a hydrogel. In some preferred embodiments, the CuAAC reaction for labeling drug molecules is optimized. In a plurality of embodiments, the binding target in the tissue sample can be identified by, for example, immunostaining, RNA hybridization, or spatially resolved molecular characterization means.
[0013] A further understanding of the nature and advantages of the present invention may be realized by reference to the remainder of the specification and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1.Click reaction ligand optimization performed with CLARITY brain slices. TBTA was 90 μM. For all additional ligands, the copper-ligand ratio was 1:2. Reactions under CC-ABPP conditions (TBTA) produced high background in vehicle controls. At 50 μM CuSO4, only BTTP gave weak labeling. Increasing the CuSO4 concentration to 100 and 150 μM provided robust labeling without significant background labeling. At least 100 μM CuSO4 was required. Unless otherwise stated, 150 μM CuSO4, 300 μM BTTP were used in all CATCH studies. Images represent the primary somatosensory cortex (S1). Scale bar, 20 μm.
[0015] Figure 2 CATCH labeling in tissues cleared by PFA fixation and hydrogel-based clearing techniques (CLARITY and SHIELD). Images are representative of S1. Scale bar, 20 μm.
[0016] Figure 3 .For efficient and homogenous drug labeling, CATCH requires that tissue samples be pre-incubated overnight in click incubation buffer (5 μM Alexa647-pyridyl-azide, 150 μM CuSO4, 300 μM BTTP, 10% DMSO in PBS) before the reaction begins. Tissue samples are then transferred to new incubation buffer. Sodium ascorbate (NaAsb) is added to the incubation buffer to obtain click reaction buffer (5 μM Alexa647-pyridyl-azide, 150 μM CuSO4, 300 μM BTTP, 2.5 mM NaAsb, 10% DMSO in PBS). Images represent S1. Scale bar, 20 μm.
[0017] Figure 4 .CATCH is compatible with drug imaging in the liver and small intestine. Scale bar, 50 μm.
[0018] Figure 5 .CATCH is compatible with molecular marker staining for cell type identification. The image shows that PF7845-yne binds NeuN-positive neurons but not lectin-positive vessels in S1. Images are representative of S1. Scale bar, 10 μm.
[0019] Figure 6. CATCH is compatible with reversible molecular marker staining. The drug-fluorophore complex is resistant to antibody washout (A). After primary antibody staining, NeuN staining can be removed without damaging click-labeled pargyline-yne positive cells. The tissue was restained with TH antibody for reversible multiple cell type identification (B). Images represent pons. Scale bar, 10 μm.
[0020] Figure 7 .CATCH can resolve drug binding at subcellular resolution. The image shows MJN110-yne binding in presynaptic terminals marked by synaptophysin staining, indicating that MJN110-yne binds to monoacylglycerol lipase (MAGL). The image represents hippocampal CA1. Scale bar, 10 μm.
[0021] Figure 8 CATCH enables spatially resolved, high-resolution pharmacology. Schematic of dose-dependent in vivo blocking studies. At low doses, the parent drug fails to completely block the target, leaving room for subsequent alkyne drug binding. At high doses, the parent drug saturates the target, eliminating alkyne drug binding (A). Zoomed-out view of PF7845 blockade in the hippocampus and cortex followed by PF7845-yne injection (1 mg / kg, 1 h, ip) at indicated doses. At 0.02 mg / kg PF7845, cortical PF7845-yne was completely blocked. However, residual unoccupied FAAH still remained in the hippocampus. Scale bar, 500 μm (B). Schematic of dose-dependent direct alkyne drug mapping. Higher target saturation should be associated with higher CATCH labeling intensity (C). Zoomed-out view of PF7845-yne binding kinetics in the hippocampus and cortex (4 h, ip). 0.1 mg / kg of PF7845-yne saturated cortical but not hippocampal FAAH. Scale bar, 500 μm (D).
[0022] Fig. 9.CATCH can distinguish potential off-target drug binding regions. PF7845 is considered a safe FAAH inhibitor, while BIA10-2474 is a FAAH inhibitor associated with clinical neurotoxicity. For both drugs, 5m / kg was used for dosing to maximize contrast for target visualization. Full coronal section at Bregma-4.4, and magnified views of the periaqueductal gray (PAG) and pontine tegmental nucleus (RtTg). BIA10-2474-yne (5mg / kg, 4 hours, ip) binds to large cell structures in the PAG of wild-type mice, but not in the PAG of FAAH- / - mice, indicating that it binds primarily to targets in the PAG. Cellular structures were found in RtTg from FAAH- / - mice treated with BIA10-2474-yne, but not in RtTg from FAAH- / - mice treated with PF7845-yne, suggesting off-target binding. Image brightness / contrast was optimized for each brain region for better visualization. Scale bar, 100 μm. DETAILED DESCRIPTION
[0023] I. Overview
[0024] A comprehensive understanding of in vivo efficacy and toxicity at high spatial and resolution remains a major unresolved challenge to realizing the full potential of chemical probes and drugs. Currently, it is not possible to determine drug binding in whole animals (multiple organ systems) at cellular and molecular resolution in mammals. Biochemical methods (such as chemical proteomics) provide excellent molecular details of drug-target interactions, but do not have the spatial resolution to identify tissue and cellular targets. Currently, imaging methods (such as PET) resolve larger tissue distributions, but cannot assess molecular and cellular specificity.
[0025] The present invention is partly based on the research carried out by the inventor, to develop a method for optical imaging of covalent drug targets in intact mammalian tissues. The method (known as Clearing Assisted Tissue Click Chemistry (CATCH)) allows specificity and robust in situ fluorescence imaging of target-bound drug molecules at subcellular resolution, and enables identification of target cell types. As exemplified herein, using well-established endogenous cannabinoid hydrolases and inhibitors of monoamine oxidase, direct or competitive CATCH not only discloses different anatomical distributions and major cell targets of different drug compounds in mouse brain, but also discloses that drugs are engaged between brain regions and in brain regions. Unexpected differences, reflecting rare cell types, and the dose-dependent target transfer across tissues, cells and subcellular compartments that cannot be obtained by conventional methods. CATCH represents a valuable and differentiated platform for studying small molecules-target interactions in vivo.
[0026] Therefore, the present invention provides new methods for analyzing the drug molecules of target binding and the related methods for identifying drug targets in tissues. The detailed steps and schemes for carrying out these methods are described in detail herein. As shown in this article, the method of the present invention can be used for analyzing drugs (for example, imaging them) at subcellular resolution in native tissues. Immunostaining, RNA hybridization or other spatially resolved molecular characterization methods can be used to identify binding targets subsequently. The in vivo tissue distribution and target identity of the drug can be determined from the same platform to obtain comprehensive on-target and off-target mapping of candidate drugs.
[0027] Unless otherwise indicated, the present invention may employ conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are fully described in the literature. (See, e.g.,
[0028] Sambrook et al., ed. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook et al., ed. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D. N. Glover ed., (1985) DNA Cloning, Volumes I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis et al. U.S. Patent No. 4,683,195; Hames and Higgin, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Miller and Calos eds. (1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu et al., eds., Methods In Enzymology, Volumes 154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell, eds., (1986) Handbook of Experimental Immunology, Volumes I to IV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1986); and in Ausubel et al. (1989) Current Protocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.). .
[0029] II. definition
[0030] The following sections provide more detailed instructions for preparing and using the compositions of the present invention and for performing the methods of the present invention. Unless otherwise defined, all technical terms and scientific terms used herein have the same meanings as those commonly understood by those of ordinary skill in the art to which the present invention belongs. The following references provide general definitions of many of the terms used in the present invention for the skilled person:
[0031] Academic Press Dictionary of Science and Technology, Morris (Ed.), Academic Press (1st edition, 1992); Oxford Dictionary of Biochemistry and Molecular Biology, Smith et al. (Eds.), Oxford University Press (revised edition, 2000); Encyclopaedic Dictionary of Chemistry, Kumar (Ed.), Anmol Publications Pvt. Ltd. (2002); Dictionary of Microbiology and Molecular Biology, Singleton et al. (Eds.), John Wiley & Sons (3rd edition, 2002); Dictionary of Chemistry, Hunt (Ed.), Routledge (1st edition, 1999); Dictionary of Pharmaceutical Medicine, Nahler (Ed.), Springer-Verlag Telos(1994); Dictionary of Organic Chemistry, Kumar and Anand and (Eds.), Anmol Publications Pvt. Ltd. (2002); and A Dictionary of Biology (Oxford Paperback Reference), Matin and Hine (Eds.), Oxford University Press (4th Edition, 2000).
[0032] Additionally, the following definitions are provided to assist the reader in practicing the present invention.
[0033] It should be noted that, unless the context clearly indicates otherwise, nouns as used herein and in the appended claims without quantifiers refer to one or more. It should also be noted that the claims may be drafted to exclude any optional elements. Therefore, this statement is intended to serve as an antecedent basis for the use of such exclusive terms such as "only", "only", etc., or the use of "negative" limitations associated with the recording of claim elements.
[0034] As used herein, the term "alkyne-based compound" refers to a small molecule drug or polymer molecule comprising at least one reactive alkynyl group. An "alkynyl group" is an unsaturated, straight or branched chain or cyclic hydrocarbon group consisting of at least one carbon-carbon triple bond. In one embodiment, an alkyne-based substrate preferably comprises at least one terminal alkynyl group (-C≡CH).
[0035] As used herein, the term "azide-based substrate" refers to a small molecule or a polymer molecule comprising at least one azide group. Substrates contemplated in the present invention may include soluble reagents or solid immobilized reagents, such as surface immobilized reagents.
[0036] The term "specific binding" or "specifically binds to" or "has specificity for" refers to the binding of a binding moiety to a binding target, such as the binding of an immunoglobulin to a target antigen, e.g., an epitope on a specific polypeptide, a peptide, or other target (e.g., a glycoprotein target), and is intended to mean binding that is measurably different from non-specific interactions (e.g., a non-specific interaction may be binding to bovine serum albumin or casein). Specific binding can be measured, for example, by determining the binding of a binding moiety or immunoglobulin to a target molecule compared to binding to a control molecule. For example, specific binding can be determined by competition with a control molecule similar to the target (e.g., an excess of unlabeled target). In this case, if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target, specific binding is indicated. As used herein, the term "specifically binds to" or "specifically binds to" or "has specificity for" a specific polypeptide or an epitope on a specific polypeptide target can be, for example, measured by a molecule having a K of less than or equal to 1 for the target. d By "specific binding" is meant at least about 200 nM, or at least about 150 nM, or at least about 100 nM, or at least about 60 nM, or at least about 50 nM, or at least about 40 nM, or at least about 30 nM, or at least about 20 nM, or at least about 10 nM, or at least about 8 nM, or at least about 6 nM, or at least about 4 nM, or at least about 2 nM, or at least about 1 nM or greater. In some cases, the term "specific binding" refers to a combination in which a molecule binds to a specific polypeptide or an epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
[0037] The terms "conjugate," "conjugated," and "conjugated" refer to any and all forms of covalent or non-covalent linkage, and include, but are not limited to, direct genetic or chemical fusion, coupling through a linker or cross-linker, and non-covalent association.
[0038] As used herein, the term "tissue clearing" refers to a process that has the effect of adjusting, matching or homogenizing the refractive index (RI) of tissue, generally resulting in increased transparency of the tissue. The transparency of the tissue can be quantitatively determined by optical absorption spectrophotometry (e.g., measuring light transmission through the tissue) or confocal microscopy.
[0039] As used herein, the term "refractive index" or "RI" refers to the ratio of the velocity of radiation (eg, in electromagnetic radiation or light) in one medium (eg, air, glass, or a vacuum) to the velocity of the radiation in another medium.
[0040] The term "derivative" refers to a compound / part that is structurally similar to a parent compound / part but is different from the parent compound / part in terms of one or more components, functional groups, atoms, etc. Derivatives can be formed by chemical reactions from the parent compound / part. The difference between the derivative and the parent compound / part may include, but is not limited to, replacing one or more functional groups with one or more different functional groups, or introducing or removing substituents of one or more hydrogen atoms. In some forms, the derivative may also be different from the parent compound / part in terms of protonation state. In some forms, the derivative may be derived from the parent compound / part by acid-base reaction. Preferably, the derivative retains the biological activity of the parent compound / part, such as at least 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65% and 60% of the biological activity of the parent compound / part. In some forms, the derivative has higher activity compared to the parent compound / part.
[0041] The term "target" or "binding target" is used in the broadest sense and specifically includes polypeptides, but is not limited to nucleic acids, carbohydrates, lipids, cells, and other molecules that may or may not have biological functions when they occur naturally. In some preferred embodiments herein, the target is a cell surface antigen or receptor.
[0042] The term "antigen" refers to an entity or fragment thereof that can bind to an immunoglobulin or trigger a cellular immune response. An immunogen refers to an antigen that can elicit an immune response in an organism, particularly an animal, more particularly a mammal (including a human). The term antigen includes regions known as antigenic determinants or epitopes as defined above.
[0043] III. Tissue clearing and delipidation
[0044] The present invention provides methods for detecting drug targets in mammalian tissues at cellular resolution and for analyzing drug molecules (e.g., imaging them in situ). Drug molecules suitable for the analysis of the methods of the present invention may have any chemical properties. These include, for example, small molecule compounds, peptides, proteins, antibodies, nucleic acids, lipids, polysaccharides, or any combination thereof. In some embodiments, the methods of the present invention relate to the analysis of small molecule drugs. In some preferred embodiments, the drug molecule is an alkyne-based compound comprising an alkyne group or its analog suitable for click chemistry reactions. In some preferred embodiments, the drug molecule to be analyzed by the methods of the present invention is a covalent drug. Covalent drugs block protein function by forming a specific bond between a ligand and a target protein. Compared with a reversible mechanism of action, a covalent mechanism of action can provide many pharmacological advantages; these advantages include enhanced efficacy, selectivity, and prolonged duration of action.
[0045] According to the method of the present invention, a tissue sample is first obtained from a mammalian subject to which a drug molecule has been administered. The tissue sample is then transparentized with a degreasing agent. The transparentized tissue sample is then subjected to a CuAAC reaction to label the drug molecule. Further analysis (e.g., imaging) may be performed to analyze the drug molecule in situ (e.g., its spatial distribution) and / or identify the target of the drug molecule at a cellular or subcellular resolution.
[0046] The degreasing of the tissue sample separated from the object can be carried out with a variety of techniques known in the art and conventional practice. In general, these include hydrogel-based tissue clearing, hydrophobic-based tissue clearing, hydrophilic tissue clearing and other mixed tissue clearing methods, such as combining hydrogel-based tissue clearing and hydrophobic-based tissue clearing. In some embodiments, defatting can be performed to make the tissue clear using the method specifically described herein (e.g., HYBRiD, CLARITY and SHIELD). Tissue clearing based on hydrogel involves embedding the tissue sample in a hydrogel matrix to produce a cross-linked tissue / gel mixture containing fixed proteins and RNA. These methods use ionic detergents for degreasing, which can be enhanced by electrophoresis without causing significant loss of biomolecules. See, for example,
[0047] Chung et al., Nature 497, 332-337, 2013; Murray et al., Cell 163, 1500-1514, 2015; Ku et al., Nat.Biotechnol.34, 973-981, 2016; Woo et al., Exp.Mol.Med.48, e274, 2016; Woo et al. al., Biochem.Biophys.Res.Commun.524, 346-353, 2020; Woo et al., Int.J.Mol.Sci.22, 2892, 2021; Gradinaru et al., Annu.Rev.Biophys.47, 355-376, 2018; and Choi et al. al., Cell184, 4115-4136, 2021.
[0048] Hydrogel-based approaches have the advantages of retaining endogenous FP signals, maintaining a higher proportion of biomolecules, and better preserving brain anatomy and ultrastructure. The disadvantage is that it generally involves longer and more complex protocols (compared to hydrophobic and hydrophilic approaches) when in situ hydrogel polymerization is required. It may also require active (electrophoretic) labeling and clearing.
[0049] The methods of the present invention can also utilize hydrophobic (organic solvent-based) clearing protocols. These methods rely on the use of organic solvents (e.g., ethanol, methanol, tetrahydrofuran (THF) and tert-butyl alcohol) for tissue dehydration, defatting and permeabilization. See, for example, Dodt et al., Nat. Methods 4, 331-336, 2007; Renier et al., Cell 159, 896-910, 2014; Erturk et al., Nat. Protoc. 7, 1983-1995, 2012; and Pan et al., Nat. Methods 13, 859-867, 2016. Most known protocols for hydrophobic clearing involve simple tissue immersion (passive clearing) in a graded series of gradually increasing solvent concentrations. However, active clearing schemes in which solvents are perfused through the circulatory system allow the whole rodent body and large organs (e.g., human brain) to be cleared. Further incubation in dichloromethane (DCM) can improve tissue defatting in large samples, but at the expense of reducing the fluorescence of fluorescent proteins (FP). After dehydration, the sample is immersed in a clearing solution consisting of a mixture of benzyl alcohol and benzyl benzoate (BABB) or dibenzyl ether (DBE) to achieve RI homogenization and thus transparency. Tissue clearing based on hydrophobicity provides a very fast and reproducible scheme, requiring only simple immersion. It has higher clearing performance (transparency). However, endogenous FP signals are lost in tissue clearing based on hydrophobicity. There is a complete loss of lipids and related biomolecules, and proteins and nucleic acids may also be lost. In addition, tissue clearing based on hydrophobicity may require solvent-resistant materials and optical elements, and involves the use of volatile and toxic solvents.
[0050] The tissue clearing in the method of the present invention can also utilize hydrophilic reagents. Some examples of suitable hydrophilic reagents include different detergents for permeabilization and degreasing (e.g., Triton-X100, saponin, sodium dodecyl sulfate (SDS), etc.), and high refractive index aqueous solutions containing sugars (fructose, sucrose, sorbitol), urea, amino alcohols, or different combinations of the former. See, e.g., Ke et al., Nat. Neurosci. 16, 1154–1161, 2013; Hama et al., Nat. Neurosci. 14, 1481–1488, 2011; Susaki et al., Cell 157, 726–739, 2014; Kuwajima et al., Development 140, 1364–1368, 2013; Yu et al., Sci. Rep. 8, 1964, 2018; and Zhu et al., Proc. Natl. Acad. Sci. USA 116, 11480–11489, 2019. The advantages of hydrophilic tissue clearing protocols are preservation of endogenous FP signals, use of safer reagents, and compatibility with standard materials and optical components. Disadvantages are that hydrophilic tissue clearing may require long incubation times, and protocols using high detergent concentrations can result in the loss of lipids and associated biomolecules, proteins, and nucleic acids.
[0051] In some embodiments of the present invention, defatting can be performed with the specific tissue clearing scheme exemplified herein to make the tissue transparent. For example, the defatting of some tissue samples can be performed with CLARITY (clear lipid-exchanged acrylamide-hybridized rigid imaging-compatible tissue-hydrogel), which is a hydrogel-based tissue clearing technique exemplified herein (see, for example, Chung et al., Nature 497, 332–337, 2013). CLARITY converts intact tissue into a nanoporous hydrogel hybrid form (crosslinked with a three-dimensional network of a hydrophilic polymer), which is fully assembled but optically transparent and macromolecularly permeable. CLARITY can achieve complete tissue in situ hybridization, immunohistochemistry, and antibody labeling. This allows for fine structural analysis of clinical samples in a form suitable for detecting physiological functions and disease bases. Using CLARITY, fixed tissue (e.g., brain tissue samples) is incubated and stirred with A1P4 hydrogel, as specifically exemplified herein. Degassing and washing are then performed, and the reaction is then labeled. In some embodiments, another hydrogel-based tissue clearing method SHIELD described herein (stabilization under harsh conditions via intramolecular epoxide linkages to prevent degradation) can be used. The degreasing method uses epoxide monomers to form controlled intramolecular crosslinks and intermolecular crosslinks with biomolecules. SHIELD retains protein fluorescence and antigenicity, transcripts, and tissue structures under a wide variety of harsh conditions. See, for example, Park et al., Nat. Biotechnol. 37, 73-83, 2019. In some other embodiments, hydrophobic tissues can be made transparent by fDISCO and iDISCO exemplified herein, which use THF and methanol to remove lipid components. More detailed guidance for these two tissue clearing protocols is provided in the published literature, for example, Renier et al., Cell 159, 896-910, 2014; Qi et al., Sci. Adv. 5, eaau8355, 2019; and Erturk et al., Nat. Protoc. 7, 1983-1995, 2012.In other additional embodiments, the hydrophilic tissue can be transparentized with CUBIC3.0 to remove lipids with a water-soluble detergent. The tissue transparentization method can be carried out as described herein or as disclosed in the literature (e.g., Tainaka et al., Cell Rep 24, 2196-2210, 2018).
[0052] IV. Labeling of drug molecules in cleared tissue samples by click reaction
[0053] Once the tissue sample has been transparentized and defatted with any of the above-mentioned schemes, the drug molecules or their metabolites present in the tissue sample are subsequently labeled. Labeling is achieved by attaching or attaching a detectable label (e.g., a fluorescent agent) to a drug molecule or its metabolite. In some preferred embodiments, the drug molecule or its metabolite is labeled with a fluorophore by a click chemistry reaction (or click reaction). Click chemistry is defined as any chemical reaction that allows high yields, does not produce by-products or produces easily removable by-products, has stereospecificity, produces physiologically stable products, exhibits large thermodynamic driving forces, and has simple reaction conditions. See, for example, Kolb et al., Angew. Chem., Int. Ed. 2001, 40, 2004–2021; Kolb et al., Drug Discovery Today 2003, 8, 1128–1137. Unless otherwise stated, the click reaction used in the practice of the present invention is a CuAAC reaction. The CuAAC click reaction is well known in the art and is conventionally practiced. It is a type of Huisgen 1,3-dipolar cycloaddition based on the formation of 1,4-disubstituted [1,2,3]triazoles between terminal alkynes and aliphatic azides in the presence of copper. This reaction has found increasing application in medicinal chemistry in all aspects of drug discovery, for example for the generation of lead compounds by combinatorial approaches. Bioconjugation by click chemistry has found rigorous application in proteomics and nucleic acid research. Click reactions are used to label and detect molecules in samples that would be compromised by direct labeling or antibody-based secondary detection techniques. Click labels are small enough to easily penetrate complexed samples, and the selectivity and stability of the click reaction provide high sensitivity and low background signal. In the practice of the method of the present invention, labeling of cleared tissue samples can be readily performed according to protocols well known and routinely practiced in the art.
[0054] In some embodiments, the click reaction used in the method of the present invention for marking drug molecules or metabolites in transparent tissue samples is an optimized or improved CuAAC reaction, which provides improved imaging quality. In some embodiments, the improved click reaction uses unconventional CuAAC reaction conditions, which can achieve sufficient signal-to-noise ratio (SNR) while maintaining low background signals in vehicle controls. In some embodiments, the improved click reaction uses a newer generation of click reaction ligands or azide-based substrates. Some examples of such newer click reaction ligands include, for example, THPTA, BTTAA, and BTTP, as exemplified herein. In some embodiments, the improved click reaction uses a Cu concentration that is not commonly used in conventional CuAAC reactions. As exemplified herein, some methods of the present invention can use a Cu concentration of about 100 μM to about 300 μM in a click reaction. In some embodiments, a Cu concentration of about 100 μM to about 150 μM can be used. In a preferred embodiment, the click reaction ligand used is BTTP, and the Cu concentration used is 150 μM, as exemplified herein.
[0055] In some embodiments, the optimized click reaction involves a pre-incubation step of the transparent tissue sample before the click reaction begins. In this step, the transparent tissue sample is pre-incubated in an incubation buffer for a period of time sufficient to adjust the tissue to homogenize and label the entire tissue. In multiple embodiments, the pre-incubation period can be at least 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours or longer. In some embodiments, the incubation buffer may include Alexa647-pyridylmethyl-azide, CuSO4, BTTP and DMSO at appropriate concentrations as described in detail herein. After pre-incubation, the treated tissue sample is then transferred to the click reaction buffer to start the click reaction. As exemplified herein, the click reaction buffer may include a fresh incubation buffer to which sodium ascorbate (NaAsb) has been added.
[0056] As a specific exemplary embodiment of the optimized click reaction, the incubation buffer may contain 5 μM Alexa647-picolyl-azide, 150 μM CuSO4, 300 μM BTTP, 10% DMSO in PBS. The pre-incubation period may last for about 1 to 16 hours. The complete click reaction buffer contains 5 μM AF647-picolyl-azide, 150 μM CuSO4, 300 μM BTTP, 2.5 mM sodium ascorbate, and 10% DMSO in PBS. A detailed protocol for performing the optimized click reaction is exemplified herein.
[0057] V Sutra Analysis of clearing and labeled tissues
[0058] In order to determine the presence of drug molecules in tissues obtained from subjects to whom the drug is administered and / or to identify their targets, the transparentized and labeled tissues are then analyzed by appropriate means. Depending on the tissue sample and detectable label used in the click reaction, a variety of physical, optical, immunochemical or biological methods can be used. These methods include, for example, confocal microscopy, fluorescence imaging, mass spectrometry imaging, multiphoton microscopy, fluorescence microscopy and positron emission tomography (PET). In various embodiments, in situ analysis of drugs in biological samples can be easily performed using these and other tools routinely practiced in the art. See, for example,
[0059] Diaspro et al., Microsc. Res. Tech. 1999; 47: 163-4; Denk et al., Science 1990; 248: 73-6; Imbert et al., Methods Mol. Biol. 1999; 122: 341-55; Tadrouset al., J. Pathol. 2000; 191: 345-54; Xue et al. al., Sci.Adv.2018;4:eaat9039; McMahon et al., Proc.SPIE Int.Soc.Opt.Eng.2020February;11219; and Bian et al., STAR Protocols2022;3:101600.
[0060] In some preferred embodiments, the spatial distribution of drug molecules and target interactions can be first examined in transparentized tissues by imaging means. In addition to the confocal microscopy exemplified herein, other suitable imaging means, such as fluorescence lifetime imaging, Raman imaging, and autoradiography, can also be employed in the practice of the present invention.
[0061] As mentioned above, drug molecules or metabolites are labeled with detectable labels (such as fluorophores) by CuAAC reactions. Then transparent and labeled tissue samples can be checked by suitable means to analyze labeled drug molecules in tissues. In some preferred embodiments, the presence of drug molecules in tissues and / or the interaction of drug molecules with their targets are analyzed with confocal microscopy, as exemplified herein. Confocal microscopy is based on irradiating biological samples (such as tissues) with excitation light, and then detecting the emitted light. This means that only fluorescent objects can be checked. In most cases, biological samples are made to emit fluorescence by using labels (confocal epifluorescence (confocal epifluorescence)) for specific intracellular or intra-organizational structures. For many years, the spontaneous autofluorescence (confocal epitransmission (confocal epitransmission)) of many biomolecules or the ability of opaque surface reflected light (confocal reflectance (confocal reflectance)).
[0062] In addition to imaging, cell type registration can also be performed on tissue samples that have been transparentized and labeled with click reactions. In some of these embodiments, tissue samples can be stained with reagents for cell types known or suspected to express drug molecule targets. Cells expressing specific target molecules or markers of interest can be identified by a variety of assays. These include, for example, flow cytometry, immunohistochemistry, and next-generation sequencing. In some embodiments, tissue samples can be stained with antibodies or nucleic acid probes that are specific to one or more marker molecules of a cell type.
[0063] Cell markers for a large number of cell types, including diseased cells (eg, tumor cells), are well known and extensively characterized in the art. Using human immune cells for illustration, some well-characterized cell markers include, for example, CD34+, CD38-, CD45RA-, CD49+, CD90 / Thy1+ for hematopoietic stem cells (HSC); CD34+, CD38-, CD45RA-, CD90 / Thy1- for multipotent progenitor cells (MPP); CD34+, CD38+, CD10+, CD45RA+ for common lymphoid progenitor cells (CLP); CD34+, CD38+, CD7-, CD10-, CD45RA-, CD90 / Thy1-, CD135+ for common lymphoid progenitor cells (CLP); CD34+, CD38+, CD7-, CD10-, CD45RA-, CD90 / Thy1-, CD135+ for megakaryocyte-erythroid progenitor cells (MPP); For leukocyte-monocyte progenitor (MEP), they are CD34+, CD38+, CD7-, CD10-, CD45RA-, CD135-, IL3Rα-; for granulocyte-monocyte progenitor (GMP), they are CD34+, CD38+, CD10-, CD45RA+, CD123+, CD135+; for natural killer cells, they are CD3-, CD56+, CD94+, NKp46+; for T cells, they are CD3+; for B cells, they are CD19+; for monocytes, they are CD14+; for macrophages, they are CD11b+, CD68+, CD163+; for dendritic cells, they are CD11c+ and HLA-DR+; for neutrophils, they are CD11b+, CD16+, CD18+, CD32+, CD44 +, CD55+; for eosinophils, CD45+, CD125+, CD193+, F4 / 80+, Siglec-8+; for basophils, CD19-, CD22+, CD45low, CD123+; for mast cells, CD32+, CD33+, CD117+, CD203c+, FcεRI+; for erythrocytes, CD235a+; for megakaryocytes, CD41b+, CD42a+, CD42b+, CD61+; and for platelets, CD41+, CD42a+, CD42b+, CD61+. For any of these cell types, any one or combination of these known markers can be explored to determine the cell type in the tissue that is targeted by the drug molecule.
[0064] In some embodiments, the cell marker to be detected from the tissue sample is specific to dead cells. In some of these embodiments, the cell marker is a tumor-specific marker. Some examples of such markers include but are not limited to HER2 (ERBB2), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), CA125, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), CA19-9, CA15-3, CA27-29, lactate dehydrogenase (LDH) and neuron-specific enolase (NSE).
[0065] Example
[0066] The following examples are provided to further illustrate the present invention but not to limit its scope.
[0067] Example 1. CATCH enables in situ specific labeling and imaging of drugs
[0068] Over the past decade, there has been a renewed interest in chemical probes and drugs that operate via covalent mechanisms, as their irreversible binding to protein targets can improve binding efficacy to challenging targets and provide excellent pharmacodynamic properties in vivo. Irreversibility also makes it particularly important to understand the cellular targets of covalent drugs with high precision to minimize toxicity. In order to establish a model system in which drug target visualization can be evaluated, the inventors developed a set of well-characterized covalent inhibitors of endocannabinoid hydrolases that have the potential to treat a range of human neurological disorders. Initial experiments were performed using the fatty acid amide hydrolase (FAAH) inhibitor PF-04457845 (or PF7845), whose urea backbone forms a covalent bond with the active serine residue of FAAH to irreversibly inhibit enzyme activity. Previous work has shown that the alkyne-modified analog PF7845-yne retains similar selectivity to PF7845 and is able to selectively detect FAAH in whole brain lysates by CC-ABPP combined with in-gel fluorescence readout (SDS-PAGE) (Niphakis et al., ACS Chem Neurosci 3, 418-426, 2012). However, attempts to image drug-bound FAAH directly in brain slices from mice treated with PF7845-yne with an azide-Alexa647 label under CC-ABPP conditions failed to reveal cellular targets due to poor SNR.
[0069] The inventors reasoned that the complex composition of tissues, particularly dense lipid membranes, might hinder CuAAC reactions. Therefore, the inventors tested whether CLARITY, a polyacrylamide-based aqueous clearing method, could improve the SNR of CuAAC labeling. After applying CC-ABPP click conditions to brain slices from mice treated with PF7845-yne, CLARITY treatment presented a membrane-like fluorescence signal in the primary somatosensory cortex (S1) after clicking with Alexa-647-pyridylmethyl-azide, consistent with the expected FAAH engagement. However, background nuclear signals were observed in vehicle-treated samples, indicating that a large number of side reactions occurred under this condition ( Figure 1 ).
[0070] Because a ligand is used to protect the catalytic Cu(I) from excessive reactive oxygen species (ROS) generation and side reactions with CuAAC, the inventors speculate that although the original CC-ABPP protocol using 1 mM CuSO4 and the first-generation ligand TBTA produced satisfactory results in a homogenized system, high concentrations of Cu 2+Therefore, the inventors compared a series of 2+ The newer generation ligands with higher concentrations. THPTA, BTTAA, and BTTP (Li and Zhang, 2016) significantly eliminated the background signal in vehicle-treated samples. In addition, using only 50 μM CuSO4, BTTP produced a weak but significant membrane-like signal in PF7845-yne-treated tissues ( Figure 1 ). By gradually increasing Cu 2+ concentration, the inventors found that 150 μM CuSO4 resulted in robust fluorescent labeling and minimal background staining in the control ( Figure 1 ). As expected, fluorescent labeling is strictly dependent on the presence of each component of the CuAAC reaction. Removal of any of the reaction components (CuSO4, BTTP, Alexa-647-picolyl-azide) will render click labeling ineffective. Importantly, making the tissue optically transparent using reflectance index matching alone is not sufficient to produce a satisfactory SNR, suggesting that defatting associated with tissue clearing is necessary to promote in situ CuAAC labeling. The inventors found that after tissue clearing, direct labeling of samples in the complete click reaction mixture (5μM Alexa647-picolyl-azide, 150μM CuSO4, 300μM BTTP, 2.5mM NaAsb, 10% DMSO in PBS) provided only weak labeling on the tissue surface ( Figure 3 Insufficient click labeling depth can be addressed by pre-incubating the sample in click incubation buffer (5 μM Alexa647-picolyl-azide, 150 μM CuSO4, 300 μM BTTP, 10% DMSO in PBS). In the absence of NaAsb, the Cu-BTTP complex can diffuse into the tissue before the reaction begins, ensuring a homogenous distribution of the catalytic species throughout the tissue depth ( Figure 3 ). After tissue clearing, different drug delivery routes (including oral, intraperitoneal, and subcutaneous) achieved similar results. The inventors have shown that CATCH can also be applied to non-brain peripheral tissues ( Figure 4 In addition to the liver and small intestine, the inventors have also demonstrated drug mapping in the large intestine, heart, spleen, colon, lung, kidney, and skeletal muscle. The inventors have shown that CATCH is compatible with two hydrogel-based tissue clearing technologies, CLARITY and SHIELD (Park et al., Nat Biotechnol 37, 73-83, 2019) ( Figure 2In addition, the present inventors have shown that tissues cleared by hydrophobic tissue clearing methods such as DISCO (Erturk et al., Nat Protoc 7, 1983-1995, 2012; Qi et al., Sci. Adv. 5, eaau8355, 2019; Renier et al., Cell 159, 896–910, 2014), hydrophilic tissue clearing techniques such as CUBIC3.0 (Tainaka et al., Cell Rep 24, 2196-2210, 2018), and other hybrid tissue clearing techniques such as HYBRiD (Nudell et al., Nat. Methods 19, 479–485, 2022) all produced similar labeling spectra after in situ click reaction ( Figure 2 For simplicity, the inventors chose to use the combination of CLARITY, 150 μM CuSO4 and 300 μM BTTP as the standard CATCH protocol for all subsequent experiments.
[0071] The inventors next attempted to determine whether the CATCH signal was specific for the in vivo PF7845-yne engagement of FAAH by first conducting a pharmacological blocking experiment. Pretreatment with the parent compound PF7845 completely eliminated the CATCH signal produced by PF7845-yne in the brain. The inventors also compared the PF7845-yne CATCH signal in wild-type (FAAH+ / +) mice and FAAH- / - mice. In wild-type mice, robust PF7845-yne labeling was observed throughout the brain, which showed a high degree of overlap with FAAH immunostaining and mRNA HCR (Choi et al., 2018; Sylwestrak et al., Cell 164, 792-804, 2016). In contrast, negligible PF7845-yne signals were detected in FAAH- / - mice. In summary, pharmacological and genetic results show that CATCH can visualize target engagement with high specificity in tissues from drug-treated mice. Additionally, the inventors demonstrated using multiple rounds of click reactions that drug binding can be visualized in large tissue volumes for 3D characterization.
[0072] Example 2. CATCH reveals brain-wide drug-target interactions and detects rare Target
[0073] As an example, CATCH reveals brain-wide drug-target interactions and detects rare targets. Having validated the ability of CATCH to detect interactions between PF7845-yne and FAAH, the inventors evaluated its broader utility by studying two additional covalent drug-target combinations: the structurally distinct FAAH inhibitor BIA-10-2474 (Kiss et al., 2018) and the monoamine oxidase (MAO) inhibitor pargyline (Krysiak et al., 2012). Like PF7845, BIA10-2474 has a urea backbone and inhibits FAAH by nucleophilic substitution reactions with its active serine residues (Kiss et al., 2018). In contrast, pargyline inhibits MAO by forming a covalent adduct through an oxidative addition reaction (Krysiak et al., 2012). Alkyne analogs of both drugs have been developed in previous studies (Huang et al., 2019; Krysiak et al., 2012). Following in vivo administration of PF7845-yne and BIA10-2474-yne, CATCH imaging revealed similar labeling patterns characterized by strong signals in the neocortex, thalamus, and hippocampus. In contrast, pargyline-yne administration resulted in a distinct labeling pattern enriched in the hypothalamus, pons, and lateral ventricles. CATCH allows immunostaining of FAAH after the CuAAC reaction, confirming that PF7845-yne and BIA10-2474-yne signals were primarily associated with FAAH (R 2 = 0.95 and 0.84 respectively, simple linear regression, the following R 2 No such correlation was observed in animals treated with pargyline-yne (R 2 =0.03). In contrast, MAO-A staining showed no correlation for PF7845-yne (R 2 =0.005), but had a better correlation with pargyline-yne (R 2 =0.43). Imaging at higher resolution showed that FAAH inhibitors primarily targeted neuronal-like structures in the neocortex and hippocampus. In contrast, pargyline-yne primarily bound to vasculature-like structures throughout the brain, in addition to sparse but specifically labeled neuronal-like structures in the hypothalamus and pons.
[0074] Unexpected toxicity of BIA-10-2474 in humans has been reported, possibly due to higher off-target activity compared to PF7845 (Kerbrat et al., 2016; Van Esbroeck et al., 2017). Therefore, the present inventors observed that the correlation between FAAH expression and the BIA-10-2474-yne CATCH signature was lower than that with the PF7845-yne signature (R 2 Furthermore, while most PF7845-yne and BIA-10-2474-yne CATCH signals were eliminated in FAAH- / - mice (including in S1, CA1, and periaqueductal gray (PAG)), unexpectedly, some BIA-10-2474-yne labeling remained in the pontine tegmental nucleus (RtTg) ( Fig. 9 These data indicate that BIA10-2474-yne binds to off-target sites in RtTg and also demonstrate the power of CATCH to discover drug targets at cellular resolution.
[0075] Example 3. Using CATCH and fluorescent labeling to identify target cell types
[0076] As a further example of the present invention, it was found that CATCH can be multiplexed with fluorescent markers to identify target cell types. Understanding the cell types affected by drug treatment in vivo is crucial for accurately interpreting the pharmacological mechanism of action, particularly for drugs targeting the CNS containing a variety of neural substrates and cell types. Having determined that CATCH can visualize drug targets at single-cell resolution, the inventors investigated whether it can be combined with molecular markers of cell identity to characterize and record cell target identity. The inventors showed that PF7845-yne binds to neurons in S1, but not to blood vessels, as revealed by NeuN and lectin staining ( Figure 5The inventors performed similar antibody and mRNA staining in a wide range of brain regions of interest, including but not limited to the cortex, hippocampus, hypothalamus, striatum, thalamus, basolateral amygdala, pons, cerebellum, and brainstem, and characterized the cell types to which PF7845, BIA-10-2474, and pargyline bound. In addition to neuronal and vascular staining, the inventors also identified long-range projection neurons by Ctip2 antibody staining; identified parvalbumin (PV) interneurons by PV antibody staining; identified somatostatin (SST) interneurons by SST mRNA hybridization chain reaction (HCR); identified astrocytes by glial fibrillary acidic protein (GFAP) antibody staining; identified FAAH expression by FAAH antibody staining and FAAH mRNA HCR; identified MAO-A expression by MAO-A antibody staining; identified noradrenergic (NA) neurons by tyrosine hydroxylase (TH) antibody staining; identified inhibitory neurons by VGAT-Ai14 transgenic mice; identified neuronal cell bodies by MAP2 antibody staining; and identified neuronal presynaptic terminals by synaptophysin antibody staining.
[0077] In the case of a stable polyacrylamide hydrogel network, the inventors tested the possibility of reversible, multiple marker staining (Figure 6, A). The inventors identified a small group of neuron-like structures in the pons that were NeuN negative but targeted by pargyline-yne (Figure 6, B). Based on MAO gene expression data from the Allen Brain Atlas, the inventors wanted to know whether these cells represent NA neurons in the locus coeruleus (LC) of the pons, which are usually identified by TH staining (Schmidt et al., 2019). The inventors tested this by stripping NeuN immunostaining from brain sections and staining the same samples with TH antibodies. The CATCH signal generated by CuAAC conjugation of Alexa647 is resistant to SDS elution protocols and high temperatures for removing NeuN staining, and reveals the colocalization of pargyline-yne and TH in the same cells (Figure 6, B).
[0078] Example 4. CATCH can reveal drug binding at subcellular resolution
[0079] In another example, the claimed invention is capable of detecting, at subcellular resolution, Down Revealing drug binding. Specifically, the inventors proposed whether CATCH can image drug-target interactions in subcellular compartments in tissues. To this end, the inventors used a well-characterized alkyne analog of the MAGL inhibitor MJN110 (Chang et al., ACS Chem Biol 8, 1590-1599, 2013; Niphakis et al., ACS Chem Neurosci 4, 1322-1332, 2013) to target monoacylglycerol lipase (MAGL), which is a key enzyme involved in terminating the signaling function of the endogenous cannabinoid 2-arachidonoylglycerol (2-archidonoylglycerol, 2-AG) (DiMarzo, 2018). The inventors used both pharmacological pretreatment of the parent compound MJN110 and MAGL- / - mice to determine the specificity of the MJN110-yne signal generated by CATCH.
[0080] As previously reported, the inventors found that in gel-based CC-ABPP of whole brain lysates, MJN110-yne selectively engaged MAGL at 1 mg / kg and showed extensive off-target engagement of FAAH at 20 mg / kg. Because MAGL is restricted to localization to presynaptic axon terminals, while FAAH is expressed in neuronal cell bodies, the inventors sought to determine whether CATCH could detect on-target and off-target MJN110-yne binding across subcellular compartments. The inventors focused on the well-characterized CA3 to CA1 projection in the hippocampus because it allowed us to observe both axon terminals and cell bodies in the same field of view. As expected, the inventors observed overall higher fluorescence intensity in hippocampi treated with 20 mg / kg MJN110-yne. Higher-resolution imaging combined with immunostaining for synaptophysin and microtubule-associated protein 2 (MAP2) showed that MJN110-yne signal was significantly higher at low doses (1 mg / kg, Figure 7 ) was confined to synapsin-positive axon terminals at low doses and diffused to neuronal somata at high doses (20 mg / kg). Pretreatment of animals with PF7845 significantly inhibited MJN110-yne binding in somata but not in axon terminals, indicating that these signals originated from off-target FAAH binding and on-target MAGL binding, respectively. Thus, these data indicate that CATCH can visualize drug binding to different protein targets at subcellular resolution.
[0081] Example 5. CATCH measures dose-dependent drug-target engagement.
[0082] As another example, the inventors discovered that the claimed method can be used to measure dose-dependent drug-target engagement. Finally, after determining the specificity, scalability, compatibility, and resolution of CATCH, the inventors tested whether CATCH can be used to quantitatively distinguish dose-dependent target engagement after drug administration in vivo. Recognizing that alkyne modification of drugs to produce CATCH probes has the potential to alter pharmacokinetic (PK) properties, the inventors confirmed this outcome for both FAAH and MAGL alkyne probes, which have similar blood-brain barrier (BBB) permeability and brain distribution as the parent inhibitor, but show altered in vivo half-life, so the inventors adopted a competitive strategy to visualize the dose-dependence of drug-target interactions in vivo. In this competitive CATCH method, animals are first treated with a range of doses of the parent drug, followed by a single high dose of the alkyne probe. Dose-dependent target engagement of the parent drug can be recorded based on competitive blocking of the signal in an anatomically specific manner ( Figure 8 , A).
[0083] The inventors treated mice with 0.01 to 1 mg / kg maternal PF7845, followed by 1 mg / kg PF7845-yne probe to read out the dose-dependent brain target of PF7845 by competitive CATCH. Consistent with previous in-gel analysis (Niphakis et al., ACS Chem Neurosci 3, 418-426, 2012), no target binding was detected by CATCH at 0.01 mg / kg, while complete FAAH inhibition was achieved at 0.05 mg / kg. Interestingly, the inventors found that at a moderate dose (0.02 mg / kg), FAAH was completely inhibited in the cortex, but not in the hippocampus ( Figure 8 , B). Specifically, a heterogeneous stripe pattern was observed in the hippocampal CA1 pyramidal cell layer and the DG granule cell layer, indicating submaximal drug engagement in these regions. Next, the inventors stained the brain sections with lectins to mark vasculature structures, which revealed that areas with low probe intensity (i.e., cells pre-blocked by parent PF7845) were associated with invasive vessels. In contrast, the inventors used a direct approach to visualize the dose-dependent alkynyl drug PK profile ( Figure 8 , C). Interestingly, when the middle dose of alkyne PF7845-yne (0.1 mg / kg; Figure 8 , D) When directly visualized in the hippocampus by CATCH, the inventors observed a mirror-image intensity pattern with higher probe intensity close to the vasculature.
[0084] In summary, both competitive labeling and direct labeling indicate that the PF7845-FAAH interaction may be limited by the distance between FAAH-expressing neurons and the surrounding capillaries at moderate doses. This would effectively create a drug gradient, leading to submaximal engagement in neurons further away from the vasculature. This heterogeneous distribution is unique to the hippocampus, suggesting that it may be attributed to the particularly high FAAH expression levels or the relatively low vasculature volume in this region.
[0085] Finally, because covalent inhibitors typically engage targets for prolonged periods of time, the inventors found sustained FAAH blockade of competitive probe binding even 24 hours after PF7845 administration. Overall, by complementing competitive and direct labeling strategies, CATCH can reveal dose-dependent quantitative target engagement across heterogeneous brain regions that is not easily accessible through traditional lysate-based methods.
[0086] Example 6. Exemplary Materials and Methods
[0087] Details of some protocols and materials that may be used in the practice of the present invention are described below.
[0088] Mouse model: Mice were group-housed in a 12-hour light-dark cycle and fed a standard rodent chow diet. Both male and female WT C57BL6J, FAAH- / -, MAGL- / - and VGAT-Ai14 mice of 6 to 9 weeks of age were used. VGAT-Ai14 mice were obtained by crossing VGAT-ires-cre mice with Ai14 mice. All experimental protocols were approved by the Scripps Research Institute Institutional Animal Care and Use Committee and were performed in accordance with the guidelines from the NIH.
[0089] Sample collection: The inhibitor was administered to mice by intraperitoneal (ip) injection with 10% DMSO, 2% Tween 80 in saline as a vehicle. After the drug injection was performed at the specified dose and time, the mice were heavily anesthetized with isoflurane and then perfused with ice-cold PBS, followed by 4% PFA in ice-cold PBS containing sucrose. The mouse brain or other peripheral tissues were then dissected out and then fixed overnight in 4% PFA at 4°C. The tissue was washed with PBS, embedded in 2% agarose, and sliced into 100 micron or 500 micron tissue slices by a vibrating microtome (Leica VT1000S). The tissue slices were stored in PBS containing 0.02% sodium azide at 4°C for further processing.
[0090] For in-gel ABPP analysis, after anesthesia, without perfusion or fixation, mice were decapitated and target tissues were harvested and quickly frozen in liquid N2. The brain hemisphere and liver of each mouse were washed on ice with ice-cold PBS (2 × 1mL) to remove excess blood. Tissue was homogenized in 1mL PBS and sonicated in ice-cold water for 10 minutes. Tissue was centrifuged (1000g, 10 minutes, 4°C) and then supernatant was centrifuged at high speed (100,000g, 45 minutes, 4°C). Supernatant was discarded and remaining precipitate was gently washed (2 × 0.5mL) with ice-cold PBS. Precipitate was resuspended by gently pipetting, and protein concentration was quantitatively determined by Bio-Rad DC protein assay kit. Protein group was subsequently diluted to 1.0mg / kg for immediate use or aliquoted and stored at -80°C.
[0091] For quantitative PK study, blood was collected in EDTA microtubes and mixed by cardiac puncture at each collection time point (1 hour, 2 hours, 4 hours and 24 hours). Accurate 100 μL blood was added to 400 μL ice-cold acetonitrile to inactivate blood esterase activity immediately. Subsequently, ice-cold PBS was used to perfuse mice for 2 minutes at 5mL / minute until the perfusate became clear. Four parts of the brain (forebrain, cerebellum, brainstem and backup forebrain) were collected and quickly frozen in liquid nitrogen. All blood samples extracted through acetonitrile were centrifuged for 3 minutes at 17,000 × G and supernatant was transferred to a new tube and frozen at -80 ° C until bioanalysis was performed.
[0092] In-gel click chemistry ABPP assay: Click chemistry labeling of alkyne inhibitors was performed as previously reported (Niphakis et al., ACS Chem Neurosci 3, 418-426, 2012). Click reaction buffer was prepared by mixing the following: CuSO4 (50 mM in H2O, 1.0 μL / reaction), TBTA (1.7 mM in 1:4 DMSO / t-BuOH, 3.0 μL / reaction), freshly prepared TCEP (50 mM in H2O, 1.0 μL / reaction) and 5-TAMRA azide (1.25 mM in DMSO, 1.0 μL / reaction). For every 50 μL of tissue proteome (1.0 mg / kg), 6 μL of click buffer was added. The reaction mixture was gently mixed and kept in a dark drawer at room temperature for 1 hour. The reaction was quenched by adding SDS loading buffer (4×, 18 μL) and run on SDS-PAGE.
[0093] Organizational transparency:
[0094] CLARITY: PFA-fixed tissues were incubated in A1P4 hydrogels (1% acrylamide, 0.125% Bis, 4% PFA, 0.025% VA-044 initiator (w / v)) at 4°C in 1X PBS for CLARITY embedding, as previously disclosed (Sylwestrak et al., Cell 164, 792-804, 2016). The samples were kept overnight under gentle agitation to allow adequate diffusion of the monomers. The samples were flushed with nitrogen and degassed at room temperature for 15 minutes. After degassing, the samples were polymerized at 37°C for 4 hours under gentle agitation. The samples were removed from the hydrogel and washed with 8% PBS-SDS (pH=7.0) at 40°C for two days. After clearing, the samples were washed 3×10 minutes at room temperature with PBST (pH=7.0, containing 0.2% Triton-X100, the same below) to remove residual SDS. Samples were washed briefly with PBS and then stored at 4°C in PBS containing 0.02% sodium azide.
[0095] SHIELD: SHIELD treatment was performed as previously reported (Park et al., Nat. Biotechnol. 37, 73-83, 2019). Tissue samples were incubated in SHIELD-OFF solution (25% dH2O, 25% SHIELD BUFFER solution, 50% SHIELD epoxy resin solution) at 4°C with gentle stirring for 1 day. The samples were then transferred to an equal volume of SHIELD-ON buffer and incubated at 37°C with shaking for 24 hours. The samples were washed 3×10 minutes with PBS at room temperature to remove residual SHIELD-ON buffer, and then transparentized overnight with 8% PBS-SDS (pH=7.0) at 40°C. The samples were washed 3×10 minutes with PBST at room temperature to remove residual SDS. The samples were briefly washed with PBS and then stored in PBS containing 0.02% sodium azide at 4°C.
[0096] iDISCO: iDISCO was adapted from a published protocol (Renier et al., Cell 159, 896–910, 2014). All washes with organic solvents were performed at 4°C with shaking. The fixed samples were washed in 20%, 40%, 60%, 80% methanol in H2O / 0.1% Triton X-100 / 0.3M glycine (B1N buffer, pH 7), and then washed twice with 100% methanol. The samples were then delipidated with 100% dichloromethane (DCM), washed three times in 100% methanol, and then washed in 80%, 60%, 40%, 20% methanol in B1N buffer. Each of the above washes lasted 15 minutes. The samples were then washed 3×10 minutes with PBST at room temperature to remove residual organic solvents. The samples were briefly washed with PBS and then stored at 4°C in PBS containing 0.02% sodium azide.
[0097] fDISCO: fDISCO was adapted from a published protocol (Qi et al., Sci. Adv. 5, eaau8355, 2019). The samples were washed with shaking at room temperature. The fixed samples were washed in 50%, 70%, 80% tetrahydrofuran (THF) (adjusted to pH 9 in 1×PBS) in 25% Quadrol, followed by washing twice in 100% THF. The samples were degreased with 100% DCM, then washed three times with 100% THF, followed by 80%, 70%, 50% THF washes. Each of the above washes was 15 minutes. The samples were then washed 3×10 minutes with PBST at room temperature to remove residual organic solvents. The samples were briefly washed with PBS and then stored at 4°C in PBS containing 0.02% sodium azide.
[0098] CUBIC3.0: The CUBIC protocol was adapted from the recent CUBIC3.0 protocol (Tainaka et al., Cell Rep 24, 2196-2210, 2018). The samples were transparentized with CUBIC-L buffer (10% wt N-butyldiethanolamine, 10% wt TritonX-100 in dH2O) for 4 hours at 37°C. The samples were then washed 3×10 minutes at room temperature with PBST to remove residual detergent. The samples were briefly washed with PBS and then stored at 4°C in PBS containing 0.02% sodium azide.
[0099] CATCH labeling: For 100 micron section labeling, the complete CATCH reaction buffer contained: 5 μM AF647-picolyl azide, 150 μM CuSO4, 300 μM BTTP, 2.5 mM sodium ascorbate and 10% DMSO in PBS. Tissue sections were incubated overnight at room temperature in click incubation buffer (without sodium ascorbate). The tissue was then transferred to freshly prepared incubation buffer and then 100 mM freshly prepared sodium ascorbate was added to start the reaction. After gentle stirring for 1 hour at room temperature in the dark, the reaction was quenched by adding 4 mM EDTA (pH = 8.0) in PBS and the samples were washed 3×10 minutes with PBST. After removing the click reaction mixture, the samples were stained with DAPI (1:3000 dilution of 10 μM stock solution in PBS) for 15 minutes at room temperature and prepared for RI matching and imaging. They can also be further stained for cell type registration. For 500 micron sections, 300 μM CuSO4 and 600 μM BTTP were used for incubation and reaction. To achieve complete labeling, tissues were incubated at 37°C for 2 days and subjected to 4 rounds of 1 hour click reactions at room temperature.
[0100] Immunostaining: Unless otherwise stated, samples were incubated with primary antibodies in PBST overnight at 4°C. Samples were then washed 3×30 minutes at room temperature with PBST and transferred to secondary antibodies diluted in PBST. Samples were incubated with secondary antibodies overnight at room temperature and washed 3×30 minutes with PBST. For antibody elution, imaged sections were removed and tissues were washed with 8% PBS-SDS (pH=7.0) at 60°C for 8 hours. Samples were then washed 3×10 minutes at room temperature with PBST to remove residual SDS and were ready for the next round of staining.
[0101] Hybridization chain reaction (HCR): The sample is pre-incubated in probe hybridization buffer for 30 minutes at 37°C. The sample is then transferred to a new probe hybridization buffer containing 16nM FAAH-B1 or 4nM SST-B1 probes and incubated overnight at 37°C. The sample is washed 3×30 minutes at 37°C by probe wash buffer, and then washed 2×30 minutes by 5×SSCT (750mM NaCl, 75mM sodium citrate, 0.1% Tween 20 in H2O) at room temperature. The sample is pre-incubated in amplification buffer for 30 minutes at room temperature. HCR hairpins are usually stored in 3μM, 12μL aliquots. For each hairpin aliquot, 4μL of 20×SSC (VWR, 10128-690) is added. The hairpin is heated to 95°C for 90 seconds and cooled to room temperature in a dark drawer. The hairpin is then added to a new amplification buffer to provide a final hairpin concentration of 360nM. The samples were then transferred to amplification buffer containing the hairpin and incubated overnight at room temperature. The samples were washed 3 × 30 min with 5 × SSCT and prepared for imaging.
[0102] Confocal microscopy: Labeled samples were immersed in RI matching medium (RapiClear, 1.45RI) and then mounted to glass microscope slides. Tissues were then imaged with an Olympus FV3000 confocal microscope with a 10×, 0.6NA water immersion objective (XLUMPlanFI, Olympus) for overall characterization or with an Olympus FV3000 confocal microscope with a 40×, 1.25NA silicone oil immersion (UPlanSApo, Olympus) for detailed cell type, mRNA expression, and subcellular compartment identification.
[0103] Drug in vivo concentration analysis: Compound concentrations in blood and brain regions (forebrain and brainstem) were determined by LC / MS / MS. Acetonitrile-extracted blood samples were prepared as described above, and blood calibration curves were prepared using blood from naive mice quenched according to the same protocol with serial dilutions of the test article added from 0.1 to 5000 ng / mL.
[0104] 3 volumes (in μL) of ice-cold acetonitrile: water 3: 1 (volume: volume) were added to each frozen brain tissue for compound extraction by tissue weight (mg). The tissue was then homogenized at 30 Hz for 1 minute in a tissue lyser (Tissue Lyser II, Qiagen) containing a stainless steel bead (5 mm diameter). The samples were incubated on ice for 45 minutes. Afterwards, the samples were centrifuged at 2.400 × g for 15 minutes at 4 ° C, and the supernatant was transferred to another tube. The brain homogenate of the original mouse (extracted according to the same protocol as the sample) to which the serial dilutions of the test article from 0.1 to 5000 ng / mL were added was used to draw the forebrain and brainstem calibration curves.
[0105] 10 μL of the extract was injected onto an Agilent 1290 UPLC system equipped with a G7120A pump, a G7129B autosampler, and a G1170A column manager (Agilent Technologies). ) (Waters Corporation) connected to an Acquity UPLC BEH C18 column (2.1×50 mm, 1.7 μm particle size, ) to achieve chromatographic separation. Mobile phase A consisted of 95:5 water / acetonitrile by volume, and mobile phase B consisted of 95:5 acetonitrile / water by volume. 0.1% formic acid was added to both mobile phases. The gradient started from 0% B, held for 0.5 minutes, and then linearly increased to 100% B over 4 minutes. Afterwards, solvent B was maintained at 100% for 1 minute and then switched to initial conditions over 0.1 minutes. The system was allowed to equilibrate for 1.4 minutes before the next sample injection. The flow rate was maintained at 0.6 mL / minute. The column was heated at 50°C.
[0106] Analytes were quantified using a 6460 triple quadrupole mass spectrometer equipped with an electrospray jet source (Agilent Technologies) in dynamic multiple reaction monitoring (dMRM) mode. Quantitative and qualitative transitions for each compound were optimized using authentic standards in the Optimizer software (Agilent Technologies): MJN110 (quantitative: 462.1→235, CE=10; qualitative: 462.1→165, CE=45), MJN110-yne (quantitative: 452.1→225, CE=10; qualitative: 452.1→189.6, CE=45), PF7845 (quantitative: 456.2→335.1, CE=22; qualitative: 456.2→122, CE=30) and PF7845-yne (quantitative: 470.2→349.2, CE=18; qualitative: 470.2→320.2, CE=30). For all transitions, the following parameters were kept constant: fragmentor voltage=140, battery accelerator voltage=4, polarity=positive. The total cycle time was 500 milliseconds. The source parameters were maintained as follows: drying gas temperature = 350°C, drying gas flow = 11 L / min, sheath gas temperature = 350°C, sheath gas flow = 11 L / min, nebulizer = 50 psi, nozzle voltage = 1500 V (positive), and capillary = 3500 V (positive).
[0107] Compound concentrations were calculated using Masshunter quantitation analysis software (Agilent Technologies) by extrapolating the integrated area under the curve of a calibration curve for each specific compound prepared in the same matrix as the samples.
[0108] Quantification and statistical analysis: Images were typically acquired at 10 μm intervals and analyzed with Fiji-ImageJ for 2D quantification. 3D drug binding visualization was performed by Imaris 9.2.1. All images were stored and processed in TIFF format.
[0109] Signal spectrum analysis: A 40 micron straight line was drawn on the pyramidal cells in cortical layer V on the tissue surface, as previously reported (Pan et al., Nat. Methods 13, 859-867, 2016). The signal spectrum was drawn along the line and data including background, drug-positive membrane pixels, and cell nuclei were recorded. The drawn data were then normalized by dividing each value by the average intensity of all intensity values on the same line.
[0110] Click labeling signal analysis: The intensity of individual drug-positive cells was quantified as previously reported (Pan et al., Nat. Methods 13, 859-867, 2016; Qi et al., Sci. Adv. 5, eaau8355, 2019). A 150×150 pixel (pixel size 0.414 μm) ROI was generated on the tissue surface in cortical layer V, and an automatic threshold was applied to measure the average drug-positive pixel intensity, which was I 信号 The average intensity of the remaining pixels is used as the background intensity, which is I 背景 The average labeling intensity was calculated as I 标记 =I 信号 -I 背景 The signal-to-background ratio as a function of tissue depth was calculated as I 信号 with I 背景 ratio, as previously reported (Sylwestrak et al., Cell 164, 792-804, 2016).
[0111] Regional drug abundance analysis: Images were stacked with the maximum z-projection covering the entire coronal brain slice. Different ROIs were drawn based on the mouse brain atlas (The Mouse Brain in Stereotaxic Coordinates, 2nd edition) to outline each brain region and record their average intensity. The intensity values were then normalized relative to the average intensity of the vehicle sample in the corresponding brain region.
[0112] Fluorescence intensity correlation analysis: To quantify the correlation of FAAH and MAO-A immunostaining signals with drug signals, the images were first stacked by maximum intensity projection (MIP) to obtain a single plane image. The images were then compressed 10 times to obtain a final pixel size of 24.9 μm. The entire tissue was then outlined by applying a threshold in the immunostaining channel, and each XY coordinate intensity was saved in two channels. The intensity value of each pixel was then normalized and plotted relative to the average intensity of each measurement. Univariate linear regression was applied to analyze pixel wise signal correlation.
[0113] Drug-bound capillary analysis: To quantify drug-bound abundance relative to the proximity of the nearest vessel, the pyramidal cell layer in CA1 and the granule cell layer in DG were first cropped. A threshold was applied to quantify the mean nuclear (drug-negative) pixel intensity as background intensity. Different ROIs were then cropped based on the distance to the nearest vessel, and the same threshold was applied to quantify the mean intensity in non-nuclear pixels. The mean labeling intensity was then obtained by subtracting the background intensity from the mean non-nuclear pixel intensity.
[0114] Subcellular compartment intensity analysis: For MJN110-yne characterization, images were acquired at 5 μm from the tissue surface, where the highest immunostaining signal was observed. Different cellular compartments were identified by applying a threshold in the immunostaining signal and measuring the average drug labeling intensity in the selected thresholded area. Three random squares were drawn in the nucleus of different cells and their average intensity was used as background. The intensity in the nucleus was subsequently subtracted from the intensity values recorded in the cell body or axon terminals for background adjustment. The data were then normalized relative to the average intensity of the control group as indicated in each figure legend.
[0115] Unless otherwise stated, statistical analyses were performed with Graphpad Prism 9 using conventional one-way and two-way ANOVA (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001) followed by Tukey's multiple comparison test, Multiple comparison test or Dunnett's multiple comparison test was used for evaluation. Unless otherwise stated, all data are presented as mean ± SD, and N given in the legend represents biological replicates. The whole-brain correlation between immunostaining and drug intensity was evaluated using a univariate linear regression model and R squared was calculated for each drug. For the intensity ratio between different subcellular compartments, the unpaired Mann-Whitney (Wilcoxon rank sum) test was used. Drug PK analysis was performed using t-test.
[0116] ***
[0117] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to one skilled in the art that, in light of the teachings of the invention, certain changes and modifications may be made to the invention without departing from the spirit or scope of the appended claims.
[0118] All publications, databases, GenBank sequences, patents, and patent applications cited in this specification are herein incorporated by reference as if each were specifically and individually indicated to be incorporated by reference.
Claims
1. A method for analyzing a drug molecule or its metabolites in mammalian tissue, the method comprising: (a) obtaining a tissue sample from a mammalian subject to which the drug molecule has been administered, (b) clearing the tissue sample with a degreasing agent, (c) performing a CuAAC reaction with the cleared tissue sample to label the drug molecule, and (d) examining the drug molecule in the tissue sample with an analytical means.
2. The method of claim 1, wherein the drug molecule is a small molecule.
3. The method of claim 1, wherein the drug molecule is a covalent drug.
4. The method of claim 1, wherein the degreasing agent is a hydrogel-based tissue clearing agent, a hydrophobic tissue clearing agent, or a hydrophilic tissue clearing agent.
5. The method of claim 1, wherein the drug molecule is labeled with a fluorophore through the CuAAC reaction.
6. The method of claim 1, wherein the CuAAC reaction is optimized.
7. The method of claim 6, wherein the optimized CuAAC reaction comprises Cu 2+ The concentration is about 100 μM to about 150 μM.
8. The method of claim 6, wherein the CuAAC reaction is optimized by including a pre-incubation of cleared tissue prior to initiation of the click reaction.
9. The method of claim 6, wherein the CuAAC reaction is optimized with a click reaction ligand that improves the signal-to-noise ratio.
10. The method of claim 9, wherein the click reaction ligand is BTTP, THPTA, or BTTAA.
11. The method of claim 1, wherein the drug molecule or metabolite thereof comprises an alkynyl group or an analog thereof.
12. The method of claim 1, wherein the analyzing means is an imaging means.
13. The method of claim 13, wherein the imaging means comprises confocal microscopy.
14. The method of claim 1, further comprising staining the tissue sample with a reagent specific for a cell type known or suspected to express a target of the drug molecule.
15. The method of claim 14, wherein the reagent is an antibody or a nucleic acid probe specific for the cell type.
16. A method for identifying a target of a drug molecule in a mammalian tissue, the method comprising: (a) obtaining a tissue sample from a mammalian subject to which the drug molecule has been administered, (b) making the tissue sample transparent with a degreasing agent, (c) performing a CuAAC reaction with the transparentized tissue sample to label the drug molecule, and (d) examining the drug molecule in the tissue sample with an analytical means to identify the target of the drug molecule in the tissue, thereby identifying the target of the drug molecule.
17. The method of claim 16, wherein the drug molecule is a small molecule.
18. The method of claim 16, wherein the drug molecule is a covalent drug.
19. The method of claim 16, wherein the degreasing agent is a hydrogel-based tissue clearing agent, a hydrophobic tissue clearing agent, or a hydrophilic tissue clearing agent.
20. The method of claim 16, wherein the CuAAC reaction is optimized.
21. The method of claim 16, wherein the binding target in the tissue sample is identified by immunostaining, RNA hybridization, or spatially resolved molecular characterization.
Citation Information
Patent Citations
Process for amplifying, detecting, and / or-cloning nucleic acid sequences
US4683195A
DK114165
DK124731
